CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · IEX Real-Time Price · USD
0.200
-0.043 (-17.66%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Brian G. Atwood |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
| Phone | 650-407-2376 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | 206018103 |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 2836 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2024 | 424B3 | Prospectus |
| Jul 5, 2024 | EFFECT | Notice of Effectiveness |
| Jun 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 5, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 22, 2024 | 424B3 | Prospectus |
| May 17, 2024 | 10-Q | Quarterly Report |
| May 16, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 6, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 3, 2024 | 8-K | Current Report |
| May 1, 2024 | EFFECT | Notice of Effectiveness |